Broadest consideration of socio-economic factors when setting prices for a first-line broad spectrum antibiotic across multiple priority countries*

GSK considers the most socio-economic factors when setting prices for a first-line broad-spectrum antibiotic and targets almost 90% of priority countries relevant for this product. This is comparatively broad as the industry considers only two socio-economic factors and targets only 33% of relevant priority countries, on average.

Summary  

  • What: GSK’s inter- and intra- country equitable pricing strategy for amoxicillin/clavulanate potassium (Augmentin®) considers eight socioeconomic factors and targets 88% of priority countries relevant for this product.
  • Objective: The strategy aims to ensure affordability of this product in several countries in the scope of the Index which have high burdens of disease, high inequality and/or low income levels.
  • Details: This relates to GSK’s product, amoxicillin/clavulanate potassium (Augmentin®), for different demographics in several countries in the scope of the Index.
  • Socio-economic factors considered: (1) the burden of infectious diseases, (2) healthcare system funding (and resulting out-of-pocket spending), (3) demographics and population distribution, (4) level of economic development, (5) level of inequality, (6) supply chain factors, (7) raising patient awareness and, (8) ensuring appropriate use, both by patients and physicians.

Looking closer

For a first-line treatment, GSK targets countries with a high-burden of disease and high inequality with pricing strategies that consider affordability for these populations, including several needs and constraints that impact their affordability. GSK considers eight socioeconomic factors, targeting 88% of relevant countries. It uses different equitable pricing mechanisms in different countries. The socioeconomic factors GSK considers when pricing amoxicillin/clavulanate potassium (Augmentin®) are: the burden of infectious disease, healthcare system funding (and resulting out-of-pocket spending), demographics and population distribution, level of economic development, level of inequality, supply chain factors, raising patient awareness and ensuring appropriate use by patients and physicians.

Sign up to receive updates about our work.